Life Sciences

SpringWorks Gains FDA Green Light For Genetic Disorder ...

Following the recent statement by Merck KGaA that it is in advanced talks about ...

Abcuro Secures $200 Million to Advance Ulviprubart for ...

Abcuro, a biotechnology company backed by Sanofi, has secured $200 million in Se...

Sionna Therapeutics Targets $156 Million in IPO to Adva...

Sionna Therapeutics, a biotechnology firm headquartered in Waltham, Massachusett...

AdvanCell Bags $112M in Series C Funding For Alpha Radi...

AdvanCell has raised $112 million in a Series C fundraising round supported by S...

AZ, Daiichi’s Enhertu Bags 7th FDA Green Light, First F...

Enhertu, the first antibody-drug conjugate (ADC) developed by AstraZeneca and Da...

Versant introduces another obesity biotech with “clinic...

Versant Ventures established Helicore Biopharma exactly two months after establi...

Atalanta Therapeutics Secures $97 Million to Advance si...

Atalanta Therapeutics has raised $97 million in a successful Series B financing ...

Leap Therapeutics Shifts Focus to Colorectal Cancer Aft...

Leap Therapeutics has decided to redirect its efforts towards colorectal cancer ...

Disc Medicine Refines Trial Design for EPP Drug, Target...

Disc Medicine has finalized the design for its confirmatory trial of bitopertin,...

Failed facility inspection by partners places Atara’s E...

Atara Biotherapeutics has now faced a second setback after getting a complete re...

InnoCare and Keymed License Ex-China Rights for Bispeci...

Chinese biotechs InnoCare Pharma and KeyMed Biosciences have licensed the intern...

Sling Therapeutics Challenges Tepezza in Thyroid Eye Di...

Sling Therapeutics has achieved a milestone in the development of its oral treat...

Umoja Biopharma Secures $100 Million Series C Funding f...

Umoja Biopharma has successfully closed a $100 million Series C funding round, m...

Regenxbio And Nippon Sinyaku Pen $810M Gene Therapy Agr...

Regenxbio has struck a strategic partnership valued at $810 million with Japan’s...

Gilead Sciences Broadens Scope with $1.7 Billion Partne...

Gilead Sciences is further extending its reach beyond its roots in infectious di...

Blueprint Terminates Clinical-Stage CDK2 Inhibitor Prog...

Blueprint Medicines has announced the termination of its clinical-stage CDK2 inh...